Kite Pharma has initiated a global Phase 3 trial to test the CAR T-cell therapy anito-cel in relapsed or refractory multiple myeloma.| Rare Cancer News
The FDA granted regenerative medicine advanced therapy status to the CAR T-cell therapy P-BCMA-ALLO1 for hard-to-treat multiple myeloma.| Rare Cancer News
The CAR T-cell therapy Carvykti controlled disease activity in most myeloma patients who hadn't fully responded to standard cell transplant.| Myeloma Research News